News
GlaxoSmithKline Flu Jab Linked to Sleep Disorder
GlaxoSmithKline swine flu vaccine Pandemrix has been linked to narcolepsy in young people and should be used as a last line of protectionThe agency recommended that in persons under 20 years of age, Pandemrix may only be used if...
News
Europe Issues Warnings over Actos Cancer Risk
The European Medicine Agency has supported the continued use of Takeda's diabetes medication Actos, but has opted to increase warnings regarding bladder cancer risk. The move comes after both France and Germany suspended the use...
News
American Regent Recalls Batch of Calcium Gluconate Injections
American Regent has initiated a voluntary nationwide recall of a batch of calcium gluconate injections due to the presence of silicone particulates.The recall affects lot number 1,006 of calcium gluconate injection, USP, 10%, 100mL. American Regent...
News
Valeant to acquire Ortho Dermatologics
Valeant Pharmaceuticals International announced today that Valeant's subsidiaries, Valeant Pharmaceuticals North America LLC (VPNA) and Valeant International (Barbados) SRL (VIB), have signed an agreement to acquire the assets of the Ortho Dermatologics division of Janssen Pharmaceuticals, Inc. ...
News
Abbott Confirms Long-Term Commitment to HIV Care
Abbott plans to develop two new formulations of its HIV medicines, Kaletra (lopinavir/ritonavir) and Norvir (ritonavir), to offer new formulation options for people living with HIV-1. The company is currently investigating a new powder formulation of Norvir as well...
News
Novartis begins shipment of Fluvirin® seasonal influenza vaccine to US customers
Novartis has started shipping seasonal influenza vaccine to its US customers for the 2011-2012 influenza season. Early delivery of seasonal influenza vaccine will ensure healthcare professionals have the ability to provide the earliest possible protection against influenza. Novartis plans...
News
XGEVA® (Denosumab) Granted Marketing Authorization in the European Union
Amgen (NASDAQ: AMGN) today announced that the European Commission (EC) has granted marketing authorization for XGEVA® (denosumab) for the prevention of skeletal-related events (SREs) (pathological fracture, radiation to bone, spinal cord compression or surgery to bone) in adults with...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read